Amgen posted higher-than-expected profit and said it would cut 12 to 15 percent of its workforce and close two plants.» Read More
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
U.S. drugmaker Eli Lilly reported lower-than-expected quarterly revenue as it was hurt by disappointing sales of its cancer and diabetes drugs.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
Fracking presents no risk to Novozymes’ bioenergy business, the firm’s CFO told CNBC on Thursday, after it beat first-quarter profit expectations.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Gilead's net profit nearly tripled and revenue was more than $1 billion ahead of estimates, thanks to sales of a key Hepatitis C drug.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
One of Valeant's top shareholders on Tuesday threw his support behind its proposed takeover bid for Botox-maker Allergan.
The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.
Pharmaceutical industry observers have been waiting for a rush of deals for months - and they might have finally arrived.
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are said to be pursuing a takeover of Allergan.
Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
CNBC's Meg Tirrell reports on a new scientific discovery for the more than $1.7 billion U.S. business of in vitro fertilization. Robert Frank provides insight.
For the first time in several years, Europe's IPO market looks hotter than America's. It could last for some time.
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.
Get the best of CNBC in your inbox